Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1

The compound of claim 60, represented by the formula:

• wherein:
• M, X and Y are independently C or N or O, provided that at least one of them is carbon and that when M, X, or Y is O, any adjacent member atom of the ring cannot be O;
• the bonds between M and X and between X and Y are single bonds;
• n=0, 1 or 2;
• s=1;
• t=1 or 2;
• u=0, 1, 2 or 3;
• R8 is independently selected from halogen, cyano, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkoxy, CONH2 and NR6SO2R6;
• R3, R4 and R5 are independently H, COOR6, CH2COOR6, CON(R6)2, CH2CON(R6)2, COR6, SO2R6, CONHSO2R6, CH2CONHSO2R6, alkyl, cycloalkyl, heteroaryl, aryl or arylalkyl, wherein the cyclohexyl, heteroaryl, aryl or arylalkyl groups represented by R3-R5 are optionally and independently substituted with 1-3 groups independently selected from the group consisting of halogen, cyano, (C1-C6)alkyl, halo(C1-C6)alkyl, CONH2 and NR6SO2R6, except that R4 or R5 is absent where the atom to which such R4 or R5 group would otherwise be connected is (i) O, or (ii) an N that is connected by a double bond to an adjacent atom;
• R6 is hydrogen, (C1-C4)alkyl, aryl or arylalkyl;
• Q is O or NR6;
• and
• R7 is a saturated C7-C12 bicycloalkyl or saturated C9-C12 tricycloalkyl in which 1-2 carbon atoms are optionally replaced with heteroatoms independently selected from N and O, and which is optionally substituted with 1-3 substituents independently selected from the group consisting of R6, heteroaryl, oxo-substituted heteroaryl, amino-substituted heteroaryl, heterocyclyl, oxo-substituted heterocyclyl, halogen, hydroxy, hydroxymethyl, C(NOH)NH2, CONHR6, CH2CONHR6, CON(R6)2, CH2CON(R6)2, SO2NHR6, SO2N(R6)2, CO2R6, CH2CO2R6, SO2R6, NHCOR6, NR6COR6, NHCO2R6, NR6CO2R6, NHSO2R6, and NR6SO2R6;
• or an enantiomer, diastereomer, geometrical isomer or pharmaceutically acceptable salt thereof.

A compound represented by the following structural formula:

• wherein:
• M, X and Y are independently C or N, provided that at least one of them is carbon;
• the bonds between M, X and Y are single bonds;
• n=0, 1, or 2;
• s=1;
• t=1 or 2;
• u=0, 1, 2 or 3;
• R3-R5 are independently hydrogen, A-(5-tetrazolyl), A-(cycloalkyl), A-(heteroaryl), A-(heterocyclyl), A-(aryl), A-COOR6, A-CON(R6)2, A-COR6, A-SO2R6, A-CONHSO2R6, A-CONHSO2OR6, A-CONHSO2N(R6)2, A-C≡N, alkyl, alkenyl, cycloalkyl, heteroaryl, heterocyclyl, aryl, or arylalkyl, wherein the alkyl, alkenyl, cycloalkyl, heteroaryl, heterocyclyl, aryl, A-(cycloalkyl), A-(heteroaryl), A-(heterocyclyl), A-(aryl) or arylalkyl groups represented by R3-R5 are optionally and independently substituted with 1-3 groups independently selected from the group consisting of halogen, hydroxy, cyano, —N(R6)2, —NR6C(O)N(R6)2, —NR6C(O)R6, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkoxy, CONH2, —SO2R6, —NR6SO2R6, —NR6SO2N(R6)2 and —NR6SO2OR6;
• when M, X, or Y is (—N═), then p3, p4 or p5, respectively, is 0;
• when, M, X, or Y is (—N—), (—C═), or (—CH—), then, p3, p4 or p5, respectively, is 1;
• when M, X or Y is (—C—), then p3, p4 or p5, respectively, is 2;
• and when M, X, or Y is (—C—), and, R3, R4 or R5 is connected through a double bond to M, X or Y, respectively, then p3, p4 or p5, respectively, is 1;
• A is a single bond, (C1-C6)alkylene, (C1-C6)alkenylene, (C1-C5)alkyleneCH═, C(O)(C0-C3)alkylene(C3-C6)cycloalkyl(C0-C3)alkylene, C(O)(C1-C6)alkylene, C(O)(C2-C6)alkenylene, S(O)2(C1-C6)alkylene, S(O)2(C2-C6)alkenylene, or S(O)2(C0-C3)alkylene(C3-C6)cycloalkyl(C0-C3)alkylene, each optionally substituted with up to 4 groups, R6;
• R6 is hydrogen, (C1-C10)alkyl, halo(C1-C10)alkyl, hydroxy(C1-C10)alkyl, (R6)2N(C1-C10)alkyl, aryl or arylalkyl, wherein the aryl and arylalkyl groups are optionally substituted with up to three groups independently selected from halogen, hydroxy, cyano, —N(R6)2, —NR6C(O)N(R6)2, —NR6C(O)R6, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkoxy, CON(R6)2, SO2N(R6)2, —SO2R6, —NR6SO2R6, —NR6SO2N(R6)2 and —NR6SO2OR6;
• or
• N(R6)2 is a heterocyclyl group containing at least one nitrogen atom selected from W1-W7:
• Q is O or NR6;
• and
• R7 is a saturated C7-C12 bicycloalkyl or saturated C9-C12 tricycloalkyl in which 1-2 carbon atoms are optionally replaced with heteroatoms independently selected from N and O, and which is optionally substituted with 1-3 substituents independently selected from the group consisting of R6, heteroaryl, oxo-substituted heteroaryl, amino-substituted heteroaryl, heterocyclyl, oxo-substituted heterocyclyl, halogen, hydroxy, hydroxy(C1-C6)alkyl, C(NOH)NH2, CONHR6, CH2CONHR6, CON(R6)2, CH2CON(R6)2, SO2NHR6, SO2N(R6)2, CO2R6, CH2CO2R6, SO2R6, NHCOR6, NR6COR6, NHCO2R6, NR6CO2R6, NHSO2R6, and NR6SO2R6;
• R8 is independently selected from halogen, hydroxy, cyano, —N(R6)2, —NR6C(O)N(R6)2, —NR6C(O)R6, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkoxy, CON(R6)2, SO2N(R6)2, —SO2R6, —NR6SO2R6, —NR6SO2N(R6)2 and —NR6SO2OR6;
• or an enantiomer, diastereomer, geometrical isomer or pharmaceutically acceptable salt thereof.